JPMorgan analyst Benjamin Rossi assumed coverage of Concentra (CON) with an Overweight rating and unchanged $31 price target The firm views current outpatient environment to be most favorable for companies with lower reimbursement exposure to federal funding. Concentra is the analyst’s top pick among outpatient names given the company’s lower exposure to federal spending programs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CON:
- Concentra Group Holdings: Strong Q2 Results and Raised 2025 EBITDA Guidance Support Buy Rating
- Concentra Group Reports Strong Q2 2025 Results
- Concentra Group Reports Strong Q2 2025 Financial Results
- Concentra reports 2Q adjusted EPS 37c, consensus 38c
- Concentra sees FY25 revenue $2.13B-$2.16B, consensus $2.13B